

**PRESS RELEASE**

Chassieu, 6 may 2022

**ORDINARY AND EXTRAORDINARY GENERAL MEETING TO BE HELD  
ON 24 MAY 2022  
MODALITIES THROUGH WHICH THE PREPARATORY DOCUMENTS WILL BE MADE  
AVAILABLE**

The company's shareholders are invited to attend the ordinary and extraordinary general meeting which will be held on:

**Tuesday 24 may 2022 – 9 am**

at the company registered office - 38 Avenue des Frères Montgolfier- 69680 CHASSIEU

The notice of the meeting as a notice of convocation, including the agenda and the planned resolutions, was published in the BALO (Bulletin of obligatory legal announcements) of 18 april, 2022.

The documents stipulated by article R.225-83 of the French commercial code are available to shareholders from the moment that the assembly is convened, in line with the applicable regulatory requirements:

- Any registered shareholder can, until the fifth day (inclusive) before the assembly, ask the company to send him these documents. For holders of bearer shares, this right can only be exercised upon presentation of a statement of participation in the accounts of bearer shares held by the authorised intermediary;
- Any shareholder can consult these documents at the company's headquarters during the 15 days preceding the date of the meeting.

For information, electronic voting via the VOTACCESS secure voting platform for the General Meeting of Tuesday, May 24, 2022 will be open from May 6, 2022 until Monday, May 23, 2022 at 3:00 pm (Paris time). Shareholders wishing to use this platform can consult the access conditions in the notice of meeting and on the company's website (<https://amoeba-nature.com/investisseur/assemblee-generale>).

### Disclaimer

*In the context of the coronavirus epidemic (COVID-19), the procedures for holding the Shareholders' Meeting may change depending on health and/or legal requirements. Shareholders are invited to regularly consult the section dedicated to the Shareholders' Meeting on the Company's website (<http://www.amoeba-nature.com/Investors/General-assembly>).*

*The results of the votes on resolutions will be posted on the Company's website.*

### **About Amoéba :**

Amoéba's ambition is to become the world leader in the treatment of bacterial risk in the fields of water, healthcare and plant protection. Our biological solution is an alternative to chemical products widely used today. Amoéba is currently focusing on the market of industrial cooling towers estimated at €1.7Bn (1) on a global chemical biocide market for water treatment, evaluated at €21Bn (2) and on the biocontrol market for plant protection estimated globally at €1.6Bn (3). In the future, the Company is looking at developing new applications such as chronic wound care, estimated at € 751 million (4) in the USA. Sales of associated products with healthcare, biocides and crop protection are subject to the Company being granted local regulatory market authorizations. The company is currently in the testing phase for biocidal and phytosanitary applications and does not market any products.

Created in 2010, based in Chassieu (Lyon, France) with a subsidiary in Canada and in the United States, Amoéba is quoted on the compartment C of Euronext Paris. The Company is a member of the BPIfrance Excellence network and is eligible for the PEA-PME SME equity savings plan setup. More information on [www.amoeba-nature.com](http://www.amoeba-nature.com).

(1): Amoéba data combined from sources: DRIRE 2013, Eurostat, ARHIA 2013

(2): Sources combined by Amoéba from water treaters, Freedomia, Eurostat et MarketsandMarkets

(3): Biopesticides Worldwide Market 2013, CPL, Wallingford, UK

(4): BCC Research, "Markets for Advanced Wound Management Technologies," Wellesley, MA, 2017

### **Contacts:**

#### **Amoéba**

Valérie FILIATRE

Deputy General Manager

+33 4 26 69 16 00

[v.filiatre@amoeba-nature.com](mailto:v.filiatre@amoeba-nature.com)

#### **Calyptus**

Investor & Press Relations

Nicolas HELIN / Mathieu CALLEUX

+33 1 53 65 37 90 /91

[amoeba@calyptus.net](mailto:amoeba@calyptus.net)